|
1
|
Lorenzen JM, Schauerte C, Hübner A,
Kölling M, Martino F, Scherf K, Batkai S, Zimmer K, Foinquinos A,
Kaucsar T, et al: Osteopontin is indispensible for AP1-mediated
angiotensin II-related miR-21 transcription during cardiac
fibrosis. Eur Heart J. 36:2184–2196. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
González A, Ravassa S, Beaumont J, López B
and Díez J: New targets to treat the structural remodeling of the
myocardium. J Am Coll Cardiol. 58:1833–1843. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Díez J, Querejeta R, López B, González A,
Larman M and Ubago JL Martinez: Losartan-dependent regression of
myocardial fibrosis is associated with reduction of left
ventricular chamber stiffness in hypertensive patients.
Circulation. 105:2512–2517. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen W and Frangogiannis NG: Fibroblasts
in post-infarction inflammation and cardiac repair. Biochim Biophys
Acta. 1833:945–953. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Melchior-Becker A, Dai G, Ding Z, Schäfer
L, Schrader J, Young MF and Fischer JW: Deficiency of biglycan
causes cardiac fibroblasts to differentiate into a myofibroblast
phenotype. J Biol Chem. 286:17365–17375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thum T and Lorenzen JM: Cardiac fibrosis
revisited by microRNA therapeutics. Circulation. 126:800–802. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kvakan H, Luft FC and Muller DN: Role of
the immune system in hypertensive target organ damage. Trends
Cardiovasc Med. 19:242–246. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee RC and Ambros V: An extensive class of
small RNAs in Caenorhabditis elegans. Science. 294:862–864. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Small EM and Olson EN: Pervasive roles of
microRNAs in cardiovascular biology. Nature. 469:336–342. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rawal S, Manning P and Katare R:
Cardiovascular microRNAs: As modulators and diagnostic biomarkers
of diabetic heart disease. Cardiovasc Diabetol. 13:442014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Blahna MT and Hata A: Regulation of miRNA
biogenesis as an integrated component of growth factor signaling.
Curr Opin Cell Biol. 25:233–240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Papageorgiou N, Tsalamandris S, Giolis A
and Tousoulis D: MicroRNAs in cardiovascular disease: Perspectives
and reality. Cardiol Rev. 24:110–118. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duisters RF, Tijsen AJ, Schroen B,
Leenders JJ, Lentink V, Van Der Made I, Herias V, van Leeuwen RE,
Schellings MW, Barenbrug P, et al: miR-133 and miR-30 regulate
connective tissue growth factor: Implications for a role of
microRNAs in myocardial matrix remodeling. Circ Res. 104:170–178.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thum T, Gross C, Fiedler J, Fischer T,
Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, et
al: MicroRNA-21 contributes to myocardial disease by stimulating
MAP kinase signalling in fibroblasts. Nature. 456:980–984. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Elton TS, Selemon H, Elton SM and
Parinandi NL: Regulation of the MIR155 host gene in physiological
and pathological processes. Gene. 532:1–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nazari-Jahantigh M, Wei Y, Noels H, Akhtar
S, Zhou Z, Koenen RR, Heyll K, Gremse F, Kiessling F, Grommes J, et
al: MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in
macrophages. J Clin Invest. 122:4190–4202. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seok HY, Chen J, Kataoka M, Huang ZP, Ding
J, Yan J, Hu X and Wang DZ: Loss of MicroRNA-155 protects the heart
from pathological cardiac hypertrophy. Circ Res. 114:1585–1595.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Heymans S, Corsten MF, Verhesen W, Carai
P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, Stöger L,
Wijnands E, et al: Macrophage microRNA-155 promotes cardiac
hypertrophy and failure. Circulation. 128:1420–1432. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bala S, Csak T, Saha B, Zatsiorsky J,
Kodys K, Catalano D, Satishchandran A and Szabo G: The
pro-inflammatory effects of miR-155 promote liver fibrosis and
alcohol-induced steatohepatitis. J Hepatol. 64:1378–1387. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shyu KG, Lu MJ, Chang H, Sun HY, Wang BW
and Kuan P: Carvedilol modulates the expression of
hypoxia-inducible factor-1alpha and vascular endothelial growth
factor in a rat model of volume-overload heart failure. J Card
Fail. 11:152–159. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sreejit P, Kumar S and Verma RS: An
improved protocol for primary culture of cardiomyocyte from
neonatal mice. In Vitro Cell Dev Biol Anim. 44:45–50. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tanaka A, Ide T, Fujino T, Onitsuka K,
Ikeda M, Takehara T, Hata Y, Ylikallio E, Tyynismaa H, Suomalainen
A and Sunagawa K: The overexpression of Twinkle helicase
ameliorates the progression of cardiac fibrosis and heart failure
in pressure overload model in mice. PLoS One. 8:e676422013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Weber M, Kim S, Patterson N, Rooney K and
Searles CD: MiRNA-155 targets myosin light chain kinase and
modulates actin cytoskeleton organization in endothelial cells. Am
J Physiol Heart Circ Physiol. 306:H1192–H1203. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shyu KG, Ko WH, Yang WS, Wang BW and Kuan
P: Insulin-like growth factor-1 mediates stretch-induced
upregulation of myostatin expression in neonatal rat
cardiomyocytes. Cardiovasc Res. 68:405–414. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matsusaka H, Ide T, Matsushima S, Ikeuchi
M, Kubota T, Sunagawa K, Kinugawa S and Tsutsui H: Targeted
deletion of matrix metalloproteinase 2 ameliorates myocardial
remodeling in mice with chronic pressure overload. Hypertension.
47:711–717. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tili E, Croce CM and Michaille JJ:
miR-155: On the crosstalk between inflammation and cancer. Int Rev
Immunol. 28:264–284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Faraoni I, Antonetti FR, Cardone J and
Bonmassar E: miR-155 gene: A typical multifunctional microRNA.
Biochim Biophys Acta. 1792:497–505. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Corsten MF, Papageorgiou A, Verhesen W,
Carai P, Lindow M, Obad S, Summer G, Coort SL, Hazebroek M, van
Leeuwen R, et al: MicroRNA profiling identifies microRNA-155 as an
adverse mediator of cardiac injury and dysfunction during acute
viral myocarditis. Circ Res. 111:415–425. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Roy S and Sen CK: MiRNA in innate immune
responses: Novel players in wound inflammation. Physiol Genomics.
43:557–565. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu D, Lei H, Wang JY, Zhang CL, Feng H, Fu
FY, Li L and Wu LL: CTRP3 attenuates post-infarct cardiac fibrosis
by targeting Smad3 activation and inhibiting myofibroblast
differentiation. J Mol Med (Berl). 93:1311–1325. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pan Z, Sun X, Shan H, Wang N, Wang J, Ren
J, Feng S, Xie L, Lu C, Yuan Y, et al: MicroRNA-101 inhibited
postinfarct cardiac fibrosis and improved left ventricular
compliance via the FBJ osteosarcoma oncogene/transforming growth
factor-β1 pathway. Circulation. 126:840–850. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Divakaran V and Mann DL: The emerging role
of microRNAs in cardiac remodeling and heart failure. Circ Res.
103:1072–1083. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Oury C, Servais L, Bouznad N, Hego A,
Nchimi A and Lancellotti P: MicroRNAs in valvular heart diseases:
Potential role as markers and actors of valvular and cardiac
remodeling. Int J Mol Sci. 17(pii): E11202016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Heinrich PC, Behrmann I, Haan S, Hermanns
HM, Müller-Newen G and Schaper F: Principles of interleukin
(IL)-6-type cytokine signalling and its regulation. Biochem J.
374:1–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cittadini A, Monti MG, Iaccarino G,
Castiello MC, Baldi A, Bossone E, Longobardi S, Marra AM, Petrillo
V, Saldamarco L, et al: SOCS1 gene transfer accelerates the
transition to heart failure through the inhibition of the
gp130/JAK/STAT pathway. Cardiovasc Res. 96:381–390. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu HF, Fang XY, Zhu SH, Xu XH, Zhang ZX,
Wang ZF, Zhao ZQ, Ding YJ and Tao LY: Glucocorticoid treatment
inhibits intracerebral hemorrhage-induced inflammation by targeting
the microRNA-155/SOCS1 signaling pathway. Mol Med Rep.
14:3798–3804. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lu LF, Thai TH, Calado DP, Chaudhry A,
Kubo M, Tanaka K, Loeb GB, Lee H, Yoshimura A, Rajewsky K and
Rudensky AY: Foxp3-dependent microRNA155 confers competitive
fitness to regulatory T cells by targeting SOCS1 protein. Immunity.
30:80–91. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yao R, Ma YL, Liang W, Li HH, Ma ZJ, Yu X
and Liao YH: MicroRNA-155 modulates Treg and Th17 cells
differentiation and Th17 cell function by targeting SOCS1. PLoS
One. 7:e460822012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao XD, Zhang W, Liang HJ and Ji WY:
Overexpression of miR-155 promotes proliferation and invasion of
human laryngeal squamous cell carcinoma via targeting SOCS1 and
STAT3. PLoS One. 8:e563952013. View Article : Google Scholar : PubMed/NCBI
|
